Abdalla MA, Shah N, Deshmukh H, et al. - Researchers aimed to summarize the evidence describing how various pharmacological interventions differ in their effects on lipid profiles and C-reactive protein (CRP) of women with polycystic ovary syndrome (PCOS).

• Performing a search in PubMed, MEDLINE, Scopus, Embase, Cochrane Library, and Web of Science, researchers identified 29 RCTs for inclusion.

• The lipid parameters reduced significantly in correlation with metformin, atorvastatin, saxagliptin, rosiglitazone and pioglitazone when compared with placebo or other agents.

• Significant reductions in triglycerides were recorded in correlation with atorvastatin vs placebo.

• Metformin linked with significant reductions in low-density lipoprotein cholesterol (LDL-C) when compared with placebo.

• Relative to metformin, saxagliptin was linked with significant reductions in total cholesterol.

• Atorvastatin was linked with significant reductions in C-reactive protein when compared with placebo.